This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Genetic Risk Factor for Premature Coronary Heart Disease

Angelo M. Scanu, MD

JAMA. 1992;267(24):3326-3329.

Abstract
Lipoprotein(a) (Lp[a]) can be defined as a lipoprotein particle having as a protein moiety apolipoprotein B-100 (the protein associated with low-density lipoprotein) disulfide-linked to apolipoprotein(a), the distinctive glycoprotein of Lp(a) that is homologous to plasminogen. Several forms of Lp(a) occur in the circulation. This polymorphism is related to the apolipoprotein(a) size heterogeneity that is controlled by the several alleles of the apolipoprotein(a) gene. High plasma levels of Lp(a) have been correlated with an increased risk for atherothrombotic cardiovascular disease by a mechanism that is as yet undefined. Pathogenicity may also derive from Lp(a) particles that have been modified by events believed to occur when Lp(a), after traversing the artery endothelium, reaches the intima. Aside from several promising leads, there are no universally accepted ways to lower high plasma Lp(a) levels. At this time, it is best to target efforts toward the modifiable risk factors by using appropriate diets and exercise programs and, whenever necessary, drug therapy.

(JAMA. 1992;267:3326-3329)

Author Affiliations
From the Departments of Medicine, Biochemistry, and Molecular Biology and the Lipoprotein Study Unit, the University of Chicago (Ill).

Footnotes
This article is one of a series sponsored by the American Heart Association.

Reprint requests to University of Chicago, 5841 S Maryland, MC5041, Chicago, IL 60637 (Dr Scanu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Conditional Risk Factors for Atherosclerosis
Kullo and Ballantyne
Mayo Clin Proc. 2005;80:219-230.
ABSTRACT  

Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH
Ricci et al.
Hum Reprod 2001;16:449-456.
ABSTRACT | FULL TEXT  

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects
Hermansen et al.
Diabetes Care 2001;24:228-233.
ABSTRACT | FULL TEXT  

Lipoprotein (a) and thrombogenesis in left ventricular dysfunction
Lip
Eur Heart J 2001;22:181-182.
 

Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism
von Depka et al.
Blood 2000;96:3364-3368.
ABSTRACT | FULL TEXT  

Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause
Shlipak et al.
JAMA 2000;283:1845-1852.
ABSTRACT | FULL TEXT  

Major Reduction in Plasma Lp(a) Levels During Sepsis and Burns
Mooser et al.
Arterioscler. Thromb. Vasc. Bio. 2000;20:1137-1142.
ABSTRACT | FULL TEXT  

Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)
Svensson et al.
J. Clin. Endocrinol. Metab. 1999;84:2028-2033.
ABSTRACT | FULL TEXT  

Effect of Cardiopulmonary Bypass and Heparin on Plasma Levels of Lp(a) and Apo(a) Fragments
Mooser et al.
Arterioscler. Thromb. Vasc. Bio. 1999;19:1060-1065.
ABSTRACT | FULL TEXT  

Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein
Jialal
Clin. Chem. 1998;44:1827-1832.
ABSTRACT | FULL TEXT  

Potential Health Benefits of Dietary Phytoestrogens: A Review of the Clinical, Epidemiological, and Mechanistic Evidence
Tham et al.
J. Clin. Endocrinol. Metab. 1998;83:2223-2235.
ABSTRACT | FULL TEXT  

Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells
Netea et al.
Infect. Immun. 1998;66:2365-2367.
ABSTRACT | FULL TEXT  

Should We Measure Lipoprotein Lp(a)?
Wilson and Kannel
Arch Intern Med 1997;157:1161-1162.
ABSTRACT  

Localization of Lipoprotein(a) in a Monkey Model of Rapid Neointimal Growth
Ryan et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:181-187.
ABSTRACT | FULL TEXT  

Lack of Increased Coronary Atherosclerotic Risk Due to Elevated Lipoprotein(a) in Women >=55 Years of Age
Sunayama et al.
Circulation 1996;94:1263-1268.
ABSTRACT | FULL TEXT  

Plasma Concentration of Lipoprotein(a) and the Risk of Future Stroke
Ridker et al.
JAMA 1995;273:1269-1273.
ABSTRACT  

Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia: A Prospective Trial
Illingworth et al.
Arch Intern Med 1994;154:1586-1595.
ABSTRACT  

Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men
Valentine et al.
Arch Intern Med 1994;154:801-806.
ABSTRACT  

Lipoprotein(a) in Coronary Heart Disease: Is It a Risk Factor After All?
Gurewich and Mittleman
JAMA 1994;271:1025-1026.
ABSTRACT  

A Prospective Study of Lipoprotein(a) and the Risk of Myocardial Infarction
Ridker et al.
JAMA 1993;270:2195-2199.
ABSTRACT  

Has Lipoprotein 'Little' (a) Shrunk?
Barnathan
JAMA 1993;270:2224-2225.
ABSTRACT  

Postmenopausal Hormone-Replacement Therapy
Martin and Freeman
NEJM 1993;328:1115-1117.
FULL TEXT  

Lipoprotein(a): A New Risk Factor for Vascular Disease
Valentine
PERSPECT VASC SURG ENDOVASC THER 1992;5:84-99.